Biomarkers Beyond Our Wildest Dreams
Could glycosylation patterns associated with a sleep behavior disorder predict the onset of neurodegenerative disease?
Luke Turner | | Quick Read
For someone with idiopathic REM sleep behavior disorder (iRBD), dreams can come true – literally. A loss of muscle paralysis during rapid eye movement (REM) sleep can cause patients with the disorder to physically act out their dreams. There is a pressing need to identify biomarkers that could help diagnose this condition – not just because the disorder itself can affect overall health, but also because iRBD is now considered to be an early indicator of an α-synucleinopathy related to various neurodegenerative diseases, such as Parkinson’s. Now, research that focuses on glycosylation patterns has identified certain N-glycan structures that could serve as diagnostic biomarkers for patients with iRBD (1).
Read the full article now
Log in or register to read this article in full and gain access to The Translational Scientist’s entire content archive. It’s FREE and always will be!